Welcome to the fascinating world of medical technology where innovation continues to push the boundaries of the possible.For nearly two years, under the leadership of Tim Schmid, Johnson & Johnson MedTech has been revolutionizing the industry.Each advancement reflects a deep commitment to smarter, connected, and personalized care.
As a passionate surgeon, I am constantly amazed by the progress made in our field. Technologies such as surgical robotics and pulsed field ablation are transforming the way we approach medical interventions. Tim Schmid, as global president, has played a crucial role in developing these innovations, integrating artificial intelligence to enhance the precision and safety of procedures. The introduction of the Monarch Quest system for robot-assisted bronchoscopy is a shining example of this progress. Moreover, the launch of the Polyphonic AI Fund for Surgery in collaboration with Nvidia and AWS demonstrates a clear commitment to pushing the boundaries of medical technology. Recent updates, such as FDA approval for the Varipulse PFA, reinforce J&J MedTech’s position as a leader in the treatment of arrhythmia. Finally, the completion of the first procedures with the Ottava surgical robot paves the way for a new era of robot-assisted surgery, promising even more precise and personalized outcomes for patients.
Major advancements of Johnson & Johnson MedTech in 2025: a promising report
In 2025, Johnson & Johnson MedTech continued to position itself at the forefront of global medical innovation. Under the leadership of Tim Schmid, appointed EVP and global president in October 2023, the company has made significant strides in various areas, from surgical robotics to artificial intelligence, including pulsed field ablation technologies. This report highlights flagship initiatives and major achievements that reflect the company’s commitment to smarter and more personalized healthcare.
How has Johnson & Johnson MedTech innovated in surgical robotics in 2025?
In 2025, Johnson & Johnson MedTech reached a significant milestone with the launch of its robot-assisted bronchoscopy system Monarch Quest. In March, the FDA approved this revolutionary technology, allowing for minimally invasive access and improved visualization of the airways. The Monarch system stands out for its advanced artificial intelligence algorithm and its open interface compatible with the GE HealthCare 3D mobile imaging system.
This innovation aims to accelerate the early diagnosis of lung cancer, thus facilitating a faster response for patients. Simultaneously, Johnson & Johnson MedTech also announced the first clinical uses of its Ottava surgical robot, marking a crucial milestone in the development of multi-specialty surgical techniques. For more information on the latest advancements in robotic surgery in oncology, check out this article.
What are the impacts of the Polyphonic AI Fund initiative for surgery?
In June 2025, Johnson & Johnson MedTech launched the Polyphonic AI Fund for Surgery in partnership with technology giants like Nvidia and Amazon Web Services (AWS). This initiative aims to develop artificial intelligence solutions to overcome challenges faced before, during, and after surgical interventions. By focusing on the development of AI models, data management, and responsible governance, this fund facilitates the acceleration of innovation while ensuring the ethical use of technologies.
The fund supports various projects that integrate AI into fields such as digital surgery and interventional procedures, thereby improving outcomes for patients. This strategic collaboration with Nvidia and AWS reinforces Johnson & Johnson MedTech’s position as a leader in integrating AI into modern surgical practices. Discover the winners of the MedTech 2025 advancements for health payments here.
What evolution has Johnson & Johnson MedTech’s Varipulse PFA platform undergone?
In July 2025, Johnson & Johnson MedTech received an important update for its Varipulse PFA platform, including an improvement in the irrigation flow of the Varipulse catheter. This update reflects the company’s ongoing commitment to innovation in the field of pulsed field ablation for the treatment of atrial fibrillation (AFib). The combination of PFA technology with the Carto 3 3D mapping system allows for more precise and effective interventions.
After a temporary suspension of cases in the United States in January due to neurovascular events, the resumption of sales demonstrated the robustness and improved reliability of the platform. This approach also shows how Johnson & Johnson MedTech proactively responds to feedback from the field to optimize its solutions. More details on this advancement can be found in their case study.
Who leads the electrophysiology and neurovascular group at Johnson & Johnson MedTech?
The year 2025 also marked a leadership change within Johnson & Johnson MedTech with the appointment of Michael Bodner as president of the electrophysiology and neurovascular group. After a 26-year career, Mark Dickinson, global president of neurovascular, left the company to focus on his family and explore new opportunities. Christian Cuzick has succeeded him, bringing a fresh perspective and valuable expertise.
Michael Bodner, with his experience in heart recovery and circulation restoration units, is now focusing on expanding the company’s cardiovascular portfolio. Under his leadership, Johnson & Johnson MedTech continues to integrate strategic acquisitions, such as that of Abiomed in 2022, thereby strengthening its position in the cardiac device field. For more information on the company’s internal initiatives, check out this article.
What is the significance of the first clinical uses of the Ottava surgical robot?
In April 2025, Johnson & Johnson MedTech celebrated a major milestone with the completion of the first clinical interventions using the Ottava surgical robot. This robot, designed for multi-specialty soft tissue surgery, offers unprecedented flexibility for various types of procedures, including gastrectomy, small intestine resection, and hiatal hernia repair.
After several delays and a strategic repositioning of development between 2020 and 2024, the IDE approval by the FDA allowed the launch of this innovative study. The goal is to submit Ottava for a de novo authorization, covering a wide range of procedures in general surgery. This advancement positions Johnson & Johnson MedTech as a pioneer in integrating advanced robotics in surgery, paving the way for more precise and less invasive operations.
For more information on the latest news regarding endovascular robots, visit this article.
What future projects and collaborations are planned by Johnson & Johnson MedTech?
The initiatives of Johnson & Johnson MedTech do not stop in 2025. The company plans to continue investing in cutting-edge technologies such as artificial intelligence and medical robotics, while strengthening its strategic partnerships. For instance, the collaboration with Nvidia for the development of AI solutions in surgical devices remains a priority, aiming to create smarter and more personalized care.
Moreover, Johnson & Johnson MedTech is exploring emerging areas like genomic screening with innovative partners such as Arima Genomics, which develops 3D genomic tests to revolutionize lymphoma diagnostics. These projects demonstrate the company’s commitment to staying at the forefront of medical innovation, providing solutions that meet the evolving needs of patients and healthcare professionals.
To discover the next steps of these innovative collaborations, check out this article.
What is Johnson & Johnson MedTech’s long-term vision for medical innovation?
The long-term vision of Johnson & Johnson MedTech is to redefine surgical practices and healthcare through continuous innovation and proactive adoption of emerging technologies. In 2025, the company demonstrated its commitment to creating smarter, connected, and personalized medical solutions, resulting in significant improvements in patient outcomes and care efficiency.
The integration of AI technologies and robotics in medical devices not only refines surgical interventions but also offers continuous monitoring and optimized post-operative care. By investing in dedicated AI funds and collaborating with technology leaders, Johnson & Johnson MedTech ensures it remains at the forefront of medical innovation.
To follow the evolution of health technologies and the contributions of Johnson & Johnson MedTech, visit this article.